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The goal of this review is to examine the clinical studies on d-cycloserine, a partial glutamatergic N-methyl-
D-aspartate agonist, as an augmentation strategy for exposure procedures during cognitive behavioral therapy
for anxiety disorders. Although cognitive behavioral therapy and anxiolytic medications are more effective than
placebo for treating anxiety disorders, there is still considerable room for further improvement. Traditional
combination strategies typically yield disappointing results. However, recent studies based on translational research
have shown promise to augment the neural circuitry underlying fear extinction with pharmacological means. We
discuss the current state of the literature, including inconsistencies of findings and issues concerning the drug
mechanism, dosing, and dose timing. D-cycloserine is a promising combination strategy for cognitive behavioral
therapy of anxiety disorders by augmenting extinction learning. However, there is also evidence to suggest that
d-cycloserine can facilitate reconsolidation of fear memory when exposure procedures are unsuccessful.
Keywords: Anxiety disorder, Cognitive behavioral therapy, Glutamate, D-cycloserine, NMDA, Psychotherapy,
PharmacotherapyReview
Background
Anxiety disorders are among the most common mental
health problems [1] and are associated with significantly
reduced quality of life [2]. The most effective psycho-
logical treatment for anxiety disorders is cognitive
behavioral therapy (CBT). A meta-analysis of placebo-
controlled trials of CBT yielded an average effect size of
0.73 [3,4], suggesting that many patients do not improve
after an adequate course of CBT. Similarly, traditional
pharmacological treatments for anxiety disorders, which
include monoamine oxidase inhibitors, selective sero-
tonin reuptake inhibitors, tricyclic antidepressants, and
benzodiazepines, are only modestly effective [5-7] and
the understanding of the precise psychobiological mech-
anism of these treatments remains limited [7]. In some
cases, combining anti-anxiety medication with psycho-
therapy can even cause adverse effects in the long term,
such as in the case of benzodiazepines [8].
Given the lackluster success of CBT and anxiolytic
medications, it seems reasonable to combine both treat-
ment modalities in order to maximize treatment efficacy.* Correspondence: shofmann@bu.edu
Department of Psychology, Boston University, Boston, MA 02215-2002, USA
© 2013 Hofmann et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orFor example, it may be possible that anxiolytic pharma-
cotherapy increases the ability for CBT principles to be
learned. However, such combination strategies typically
yield disappointing results as shown in a meta-analytic
review that examined all randomized placebo-controlled
clinical trials comparing combination treatment (i.e.,
CBT plus pharmacotherapy) with CBT plus placebo
across the anxiety disorders [9]. Although there are
some studies that seem to suggest that medications can
support CBT, the general results revealed only modest
benefits of combined interventions immediately follow-
ing treatment and for only some anxiety disorders. No
benefit was observed for CBT plus pharmacology over
CBT plus pill placebo at the 6-month follow-up. For ex-
ample, a well-designed clinical trial examined the rela-
tive efficacy of fluoxetine, CBT, pill placebo, CBT
combined with fluoxetine, and CBT combined with pill
placebo for social anxiety disorder [10]. The response
rates in the intention-to-treat sample were 50.9% (fluox-
etine), 51.7% (CBT), 54.2% (CBT/fluoxetine), 50.8%
(CBT/placebo), and 31.7% (placebo). Very similar effi-
cacy rates are reported for other classes of drugs and
other forms of anxiety disorders.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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well understood. It is possible that the affect-modulating
properties of anxiolytic drugs may interfere with CBT by
providing conditions for state-dependent learning, there-
by creating a unique internal context due to their effi-
cacy at modulating affect or side effects, which make the
presence of these medications discriminable to patients
[11]. It is also possible that patients attribute the fear re-
duction during CBT to the pill rather than the exposure
practices during a combination therapy, which may
negatively affect their perception of self-efficacy with re-
gard to the treatment gains [12]. Finally, CBT and anxio-
lytic drugs may operate via different and non-additive
mechanisms that are slow and suboptimal.
In recent years, a new approach of combination treat-
ment has emerged. This approach evolved from transla-
tional research on the neurocircuitry of extinction
learning. Instead of combining CBT with pharmaco-
logical agents acting as anxiolytics, CBT is combined
with pharmacological agents acting as cognitive en-
hancers to augment certain learning processes (e.g., cor-
tisol, propranolol, yohimbine) [13]. Some studies have
identified d-cycloserine (DCS) as a particularly promis-
ing pharmacological candidate for augmenting CBT.
Since the publication of previous reviews of evolving
research on DCS as an enhancer to exposure-based ther-
apies [12,14], a number of important new preclinical
studies and clinical trials have been added to the litera-
ture. These findings may shed light on the mechanism
of the observed effects. Although some of these recent
studies have failed to replicate previous successful trials,
a careful comparison between the various trials provides
some valuable insight into how and when DCS should
be used. In this review, we will first briefly review the
theoretical basis for DCS as a pharmacological enhancer,
then summarize the clinical trials testing its efficacy in
various anxiety disorders (i.e., specific phobia, social anx-
iety disorder, obsessive compulsive disorder, panic dis-
order, and post-traumatic stress disorder) and finally
discuss the clinical implications of these findings.
Theoretical basis
Learning processes
Exposure therapy is based on research on fear conditio-
ning and extinction learning [15-17]. For example,
Mowrer [17] and others (e.g., Rescorla [18], Rachman
[19]) proposed that fears are acquired through repeated
presentations of a neutral stimulus (conditioned stimu-
lus; CS) and a pain-producing or fear-eliciting stimulus
(unconditioned stimulus; US). The strength of the fear
response is determined by the association between the
CS and US, and the intensity of the unconditioned re-
sponse. The repeated presentation of the CS in the ab-
sence of the US leads to extinction, the gradual decreaseof the conditioned response. This process has been
regarded as an essential component of exposure therapy
in humans from the early beginnings of experimental
studies in psychology [20] to the contemporary field of
neuroscience [21,22].
Extinction is not simply an unlearning or forgetting
but rather a new form of learning that changes the
CS-US contingency in such a way that the CS no longer
signals an aversive event and thereby inhibits the expres-
sion of the fear response [23-26]. Evidence for this
notion comes from experiments showing spontaneous
recovery of a previously conditioned fear response [27],
renewal [28], and reinstatement of fear [29-32].
Cognitive processes
Contemporary learning theory suggests that condition-
ing and extinction result from combinations of cognitive
representations about meaningful cues (the US and CS)
and the contexts in which they associate [23-25,33].
When two stimuli are presented together, an association
forms between them. Thereafter, representation of the
CS activates representation of the US, leading to the
conditioned response. During extinction, the association
between the CS and US is weakened with each presenta-
tion of the CS that fails to be accompanied by the US.
As a result, the CS no longer predicts an aversive event.
In other words, extinction learning and exposure therapy
is associated with changes in US-CS expectancy, which
involves cognitive processes [34]. Further, other cogni-
tive changes contribute to effective extinction; for ex-
ample, it has been shown that informing subjects that
the US will not accompany the CS leads to decreased
responsivity to the CS [35].
Biological processes
Fear extinction is associated with activation in the med-
ial prefrontal cortex in rats [36] and humans [37] and
also the basolateral nucleus of the amygdala [38,39]. On
the neuronal level, extinction learning requires long-
term potentiation (LTP), which is the process by which
the repeated firing of synchronous neurons strengthens
the connection between them over time.
An important neurotransmitter involved in extinction
learning is glutamate, which is an excitatory neurotrans-
mitter in the mammalian brain. An important receptor
complex involved in this process is the N-methyl-D-
aspartate (NMDA) receptor. Activation of the NMDA
receptor requires binding of both glutamate and the co-
agonist glycine. This activation can then lead to LTP,
which is the neuronal basis for learning, including fear
conditioning [40] and extinction learning [36-39].
It has been shown that D-4-amino-3-isoxazolidone
(d-cycloserine, DCS), which is a partial agonist at the
glycine recognition site of the glutamatergic NMDA
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[41,42]. Walker and colleagues conducted the first study
examining the effects of DCS on extinction learning in
rats. In a paradigm assessing extinction by measuring
fear-potentiated startle to a conditioned stimulus, the
authors found that extinction was more successful when
preceded by administration of DCS. Other studies repli-
cated this finding [42,43].
In contrast to the animal literature, the DCS-augmen-
tation effect for extinction learning and exposure ther-
apy in humans is less consistent. As we will discuss in
more detail below, some of the inconsistent findings
might be due to the fact that DCS not only augments
extinction learning but also enhances reconsolidation of
fear memory in animals. More specifically, animal stud-
ies have shown that NMDA antagonists impair the re-
consolidation of fear memories [44-46] whereas DCS
enhances reconsolidation of fear memory in humans
when administered into the basolateral amygdala [47].
Therefore, if fear does not sufficiently decrease during
exposure therapy, fear memory reconsolidation may
occur and DCS can facilitate this counter-therapeutic
process. In other words, DCS can make “good” expo-
sures better and “bad” exposures worse. It should be
noted, however, that this is a post-hoc, yet plausible, ex-
planation for some of the negative findings reported in
some clinical trials.
It is further important to note that in animal studies,
DCS only revealed positive effects on learning when ad-
ministered in isolated (i.e., acute) dosing [48]. When ad-
ministered chronically (i.e., repeatedly over an extended
period of time), the NMDA receptor complex can be-
come desensitized, leading DCS to effectively work as an
NMDA antagonist [49]. Similarly, long-term exposure to
all major classes of antidepressants (including selective
serotonin reuptake inhibitors, tricyclics, and monoamine
reuptake inhibitors) are associated with neurochemical
changes at the glycine binding site of the NMDA receptor
complex, altering the action of DCS [50,51]. Similar effects
have been found after electroconvulsive therapy [52].
Therefore, DCS can augment extinction learning in
animals and exposure procedures in humans, but it can
also enhance fear reconsolidation. This can occur if ex-
posure procedures did not result in a sufficient reduc-
tion of fear. Moreover, there is good evidence to suggest
that chronic administration of DCS, as well as concur-
rent or past treatments with anxiolytic medication and
electroconvulsive therapy can significantly impair or
even counter - at least temporarily - the augmentation
effects of DCS for extinction learning in animals and ex-
posure therapy in humans. These issues need to be con-
sidered when reviewing the clinical trial literature of
DCS augmentation for anxiety disorders. A summary of
this literature is presented in Table 1.Clinical trials
We conducted a literature search for relevant clinical tri-
als in PubMed and Google Scholar, and also through
manual searches to identify relevant studies up until
March 2013. A study was included if it was a human
clinical trial that examined the efficacy of CBT for a
DSM-IV anxiety disorder. We used the following three
sets of search terms: (1) DCS or d-cycloserine; (2) CBT
or cognitive-behavioral or variations thereof; and (3)
anxiety or anxious or full names and abbreviations of
DSM-IV anxiety disorders. The PubMed search identi-
fied 76 studies, of which 9 met the inclusion criteria.
The Google Scholar search identified 7 additional trials
and 2 articles reporting re-analysis of previous data. All
trials included a placebo control group and employed a
randomized design. The following discusses the studies
of each of the target disorders.
Specific phobia
The first clinical trial of DCS-augmented exposure ther-
apy was conducted in patients with specific phobia [53].
This study employed a randomized, placebo-controlled
double-blind design and recruited subjects with a DSM-
IV diagnosis of acrophobia (i.e., fear of heights). All par-
ticipants received two sessions of virtual reality exposure
therapy. Those in the treatment group received either a
50 or 500 mg dose of DCS prior to exposure sessions,
whereas individuals in the control group received a pill
placebo. Results demonstrated significant symptom im-
provement in the DCS group at 1 week and 3 months
following exposure therapy, with no difference between
high and low dose groups. In addition to symptom re-
duction, participants in the DCS group also showed
greater decreases in skin conductance fluctuations dur-
ing exposures than those in the control group.
A study with spider fearful individuals [54] did not
find such exposure-enhancing effects of DCS. However,
the participants in this study did not meet the diagnostic
threshold for spider phobia. Therefore, the exposure
strategies alone might have effectively reduced fear in
this subclinical population, leaving insufficient room for
DCS enhancement. Therefore, it is possible that a ceiling
effect obscured any potential treatment-enhancing ef-
fects of DCS.
A recent trial examined the DCS augmentation effect
in treating a clinical sample of individuals with acropho-
bia [55]. Although this study used a very similar design
as employed by Ressler and colleagues [53], the results
showed that DCS did not augment exposure therapy in
the total sample. However, a post-hoc reanalysis of this
trial revealed that symptom reduction in the DCS group
was dependent on fear experienced at the conclusion of
the exposure session [56]. That is, when the session was
successful (i.e., fear was low by the end), participants in
Table 1 Characteristics and results of clinical trials of DCS-augmented CBT for anxiety disorders
Study Diagnosis N DCS Dose
(mg)
Dosing timing
(hrs before
exposure)
# of DCS
doses
CBT type (# of
exposure sessions)
Primary measures Main results (DCS vs. placebo)
Ressler et al., 2004 [53] Acrophobia 27 50 or 500 2-4 2 VRE (2) SUDS, skin conductance,
clinical self-reports
Greater subjective improvement (p < .001); greater
decrease in skin conductance fluctuations (p < .05);
greater clinical improvement (p < .02) effects were
maintained at 3-month follow-up
Guastella et al., 2007 [54] Sub-threshold
spider phobia
63 50 2-3 1 Exposure (1) SUDS, heart rate No DCS effects
Tart et al., 2013 [55] Acrophobia 29 50 −0.5a 2 VRE (2) SUDS, CGI-I No overall DCS effects.
Smits et al., 2013 [56] DCS effect on CGI-I significantly moderated by fear
level at end of exposure session (b = −.05, p < .01);
low levels of fear predicted greater symptom
improvement
Nave et al., 2012 [57] Snake phobia 20 50 1 1 Exposure (1) Snake Questionnaire No overall DCS effects.
DCS group reached top of fear hierarchy more
quickly (p < .05)
Hofmann et al., 2006 [58] SAD 27 50 1 5 Individual/group
CBT, emphasis on
exposure (5)
SPAI, LSAS Greater symptom improvement (p’s < .02); effects
maintained at 1-month follow-up
Guastella et al., 2008 [59] SAD 56 50 1 4 Group CBT,
emphasis on
exposure (4)
SPAI, LSAS Greater symptom improvement over time (p = .002).
Rodebaugh et al., in press [60] SAD 34 250 0 1 Exposure (2) SUDS Greater reduction in subjective distress between
two exposure sessions (d = 1.06)
Hofmann et al., in press [61] SAD 169 50 1 5 CBT (5) LSAS, SPDS Faster symptom improvement, global illness
severity and remission status (p’s < .05)
Wilhelm et al., 2008 [62] OCD 23 100 1 10 Exposure-based
behavior therapy (10)
YBOCS No overall DCS group effect; significant time by
group interaction (p = .02), with greater symptom
improvement in DCS group at mid-treatment.
Chasson et al. 2010 [63] Re-analysis showed DCS increased speed of symptom
improvement sixfold during the first half of treatment.
Kushner et al., 2007 [64] OCD 25 125 2 10 ERP (10) YBOCS Lower drop-out rate (p < .05); symptoms improved
more quickly during first 4 sessions (p = .02, d = .77)
Storch et al., 2007 [65] OCD 24 250 4 12 ERP (12) YBOCS No DCS effects.
Storch et al., 2010 [66] Pediatric OCD
(ages 8–17)
30 25 or 50 1 7 ERP (7) CYBOCS, CGI-S,
ADIS-CSR
Small-to-moderate DCS effects (d = .31-.47)
Otto et al., 2010 [67] PD, PDA 31 50 1 3 Brief CBT (3) PDSS, CGI-S Greater symptom and severity reduction (p = .01,
d = 1.11), maintained at follow-up (p < .05)
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Table 1 Characteristics and results of clinical trials of DCS-augmented CBT for anxiety disorders (Continued)
Siegmund et al., 2011 [68] PDA 39 50 1 3 CBT (3) PAS, CGI No overall DCS effects; statistical trend (p = 0.075)
in severely ill patients that DCS accelerated
symptom reduction
de Kleine et al., 2012 [69] PTSD 67 50 1 7-9 Prolonged
Exposure (7–9)
CAPS No overall DCS effects; DCS group more likely to
show response (odds ratio 2.83, 95 % confidence
interval [CI] 1.05–7.61).
Litz et al., 2012 [70] PTSD 26 50 0.5 4 Brief CBT (4) CAPS, PTSD Checklist DCS associated with poorer outcome on all measures
ADIS-CSR = Anxiety Disorders Interview Schedule-Clinical Severity Rating; CAPS = Clinician-Administered PTSD Scale; CBT = cognitive-behavioral therapy; CGI = Clinical Global Impression; CGI-I = Clinical Global Impression-
Improvement; CGI-S = Clinicians’ Global Impressions of Severity; CYBOCS = Child Yale Brown Obsessive Compulsive Scale; ERP = exposure/ritual prevention or exposure and response prevention; LSAS = Liebowitz social
anxiety scale; OCD = obsessive compulsive disorder; PAS = Panic and Agoraphobia Scale; PD = Panic disorder; PDA = Panic disorder with agoraphobia; PDSS = Panic Disorder Severity Scale; PTSD = posttraumatic stress
disorder; SAD = social anxiety disorder; SPDS = social phobic disorder severity scale; SPQ = spider phobia questionnaire; SPAI = social phobia and anxiety inventory; SUDS = subjective units of discomfort; VRE = Virtual
Reality Exposure; YBOCS = Yale Brown Obsessive Compulsive Scale.
aA DCS dosing timing of −0.5 hours indicates that DCS was administered 0.5 hours after the beginning of exposure.
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group. However, when the session was unsuccessful (i.e.,
fear was still high by the end), patients in the DCS group
improved less than those in the control group.
Another recent study [57] recruited individuals with
snake phobia and randomly assigned them to receive
DCS or placebo prior to exposure sessions. Both groups
responded to treatment, but the DCS group improved
more quickly than the control group. Further, the DCS
group had different ventromedial prefrontal activation in
response to snake stimuli at 1-week follow-up, as com-
pared to controls. The authors concluded that acute
DCS administration, when used as an augmentation to
exposure, resulted in lasting and qualitative changes in
prefrontal activity.
Social anxiety disorder
One of the first clinical trials examining the augmentation
effect of DCS for CBT was conducted with patients with
social anxiety disorder [58]. All patients underwent 5 ses-
sions of exposure-based CBT and were randomized to re-
ceive either 50 mg DCS or a matching placebo one hour
before each session. Exposures involved giving increasingly
difficult speeches in front of a video camera, confederate
or other group members. Results showed significantly
greater symptom improvement in the DCS group as com-
pared to the control group at post-treatment. Symptoms
further improved at 1-month follow-up for the DCS
group, and at a faster rate than for the control group,
demonstrating extended treatment effects.
This study was replicated by an independent group of
investigators using the identical design and treatment
protocol with a larger sample of patients with social anx-
iety disorder [59]. Their weekly tracking data showed that,
after the third exposure session, the DCS-augmented CBT
group already showed significantly lower social anxiety
symptoms than the placebo-augmented group.
An experimental study randomized patients with
social anxiety disorder to receive 250 mg of DCS or pla-
cebo prior to a speech challenge test. All patients
returned a second time 1 week later and were asked to
give another speech. Remarkably, only a single pre-
session administration of DCS already showed an aug-
mentation effect in patients receiving DCS as compared
to the placebo group [60].
Recently, the largest clinical trial of DCS augmentation
of CBT for an anxiety disorder was completed. This trial,
which recruited 169 patients with generalized social anx-
iety disorder, found that a 12-session course of CBT that
included 5 DCS-augmented sessions did not result in
better treatment response or remission rate relative to a
placebo-augmented CBT group. However, the DCS-
augmented CBT group showed a relatively greater rate
of improvement [61].Obsessive-compulsive disorder
Four randomized, double-blind placebo-controlled trials
of DCS augmentation have been conducted to examine
the effects of DCS augmentation to exposure therapy for
obsessive-compulsive disorder. Three of these trials were
conducted with adults [62,64,65] and one with children
[66]. All studies used exposure and response prevention
(ERP; 4–12 sessions including introductory/psychoe-
ducation sessions). Of the three adult trials, two demon-
strated that DCS augmentation facilitated the efficiency
of ERP therapy [62,64]. The trial that did not demon-
strate an effect [65] administered 250 mg of DCS 4 hours
prior to each of 12 CBT sessions. Notably, the design of
this study is significantly different than the other DCS
trials because the dosage, which was relatively high, was
administered 4 hours instead of the more common 1 or
2 hours before CBT sessions. The pediatric obsessive-
compulsive disorder trial [66] reported that the DCS-
augmented CBT group showed small-to-moderate treat-
ment effects over the CBT plus placebo group. However,
these effects did not reach the level of statistical signifi-
cance. This trial administered 25 or 50 mg of DCS 1 hour
before each of 7 CBT sessions.
It is difficult to directly compare these trials on
obsessive-compulsive disorder, because there were con-
siderable differences in the dosing of DCS (ranging
between 25 and 250 mg), dose timing (ranging between
1 hour and 4 hours before the exposures), adminis-
tration schedule, study populations (children vs. adults)
and even dropout rates (ranging between 6% and 35%;
see Table 1).
The study by Wilhelm and colleagues [62] reported that
although symptoms decreased for both groups, they were
significantly lower in the DCS group than the control
group at mid-treatment, but not at post-treatment. A re-
analysis of these results [63] showed that treatment effects
of exposure and response prevention were almost six
times faster in the DCS group during the first half of treat-
ment. This suggests that DCS augmentation did not ne-
cessarily amplify the treatment effects, but rather, made it
more efficient by accelerating symptom reduction.
This pattern of symptom change is consistent with an-
other trial that did not find group differences in symp-
tom reduction overall [64]. This study reported a faster
symptom improvement in the DCS group in sessions 4
through 6, whereas the placebo group improved faster in
sessions 8 through 10. This may reflect the short-term
efficiency-enhancing effects of DCS, which may be ob-
scured by the disappointing results in the longer term.
Panic disorder
A preliminary randomized, double-blind, placebo-control-
led trial with panic disorder outpatients examined the aug-
mentation effect of 50 mg doses of DCS, as compared to
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emphasized interoceptive exposure [67]. Patients who re-
ceived DCS-augmented exposures showed greater symp-
tom reduction from baseline to post-treatment and to
1-month follow-up than patients in the control condition.
In contrast, a similar trial did not find an overall group
effect of DCS augmentation [68]. However, the latter study
reported an accelerated symptom reduction in severely ill
patients, leading the authors to speculate that the lack of
added benefit for patients in the DCS group was due to a
floor effect for most patients. It should also be noted that
this study employed 11 sessions of CBT, as opposed to the
5 used in the Otto et al. study [67]. This is an important
difference, since chronic administration of DCS can coun-
ter and even reverse the augmentation effect.
Post-traumatic stress disorder
So far, there are two published clinical trials examining
the augmentation effect of DCS of CBT for post-
traumatic stress disorder. The first clinical trial examin-
ing DCS as an augmentation for exposure therapy in
patients with post-traumatic stress disorder failed to
show any overall group differences [69]. However, the
study reported some benefit for patients with more se-
vere baseline symptoms. This pattern is consistent with
previously described findings in panic disorder [68].
A second study reported a randomized, double-blind
placebo-controlled trial of 50 mg DCS administered 30 mi-
nutes prior to imaginal exposure for 26 Afghanistan/Iraq
veterans with combat-related post-traumatic stress dis-
order [70]. Those patients who received DCS reported
greater symptoms at post-treatment as compared to pa-
tients in the placebo condition. It is unclear why these two
DCS trials with post-traumatic stress disorder [69,70]
reported conflicting findings. It may be possible that the
inconsistency is due to methodological differences, includ-
ing the gender of patients—the majority of patients were
female in one study [69] and exclusively male in the other
[70]. Moreover, the majority of patients in the former
study were sexual trauma victims, while all patients in the
latter study were combat-related trauma victims. More-
over, and more importantly, DCS has been shown not only
to augment extinction learning, but also to enhance re-
consolidation of fear memory. A close inspection of the
distress ratings during the exposure trials in the Litz et al.
study did, in fact, show evidence of less successful within-
session extinction learning in the participants who re-
ceived DCS [70]. Therefore, in the absence of sufficient
extinction, DCS might have led to reconsolidation of the
patients’ trauma memory, leading to worse outcomes than
for patients who received placebo.
This notion is consistent with the earlier described
study in acrophobia, the only trial where DCS was
administered after exposure sessions [56]. This trialshowed that DCS only exerted the augmentation effect
over placebo when the exposure session was successful
(i.e., fear was low by the end of the session). When the
exposure session was not successful (i.e., the fear was
still high at the end of the session), DCS patients im-
proved less than those in the placebo group, consistent
with the notion that DCS can augment both extinction
learning and fear reconsolidation.
Discussion
Basic research in animal extinction learning has recently
been translated into novel treatment strategies for anx-
iety disorders. The result of this translational work has
identified d-cycloserine as a possible cognitive enhancer
to augment exposure strategies during CBT. This
represents a fruitful example of translational research,
whereby neuroscience has provided a novel, theoretically
meaningful target for exploration in treatment realms.
Following the initial excitement of early DCS augmenta-
tion treatment trials, a number of clinical trials have
failed to replicate previous successes or have provided
inconsistent results.
Specifically, DCS appears to augment a brief course of
virtual reality exposure in patients with acrophobia [53],
but did not show this augmentation effect in a replica-
tion study [54] or in subclinical spider-fearful individuals
[54] and individuals with snake phobia [57]. Positive re-
sults were found in patients with social anxiety disorder
[58-60]. The largest DCS augmentation trial to date
showed that DCS was not associated with higher re-
sponse or remission rates, as compared to placebo, but
with a faster rate of improvement [61]. In two trials with
adult obsessive-compulsive disorder patients, DCS aug-
mented the efficacy of ERP [62,64]. One trial reported
negative results, but this study was markedly different
from the other trials in dosing and dose timing of DCS
[65]. The only obsessive-compulsive disorder trial with a
pediatric sample showed small to moderate, but non-
significant, effects of DCS over placebo [66]. Mixed re-
sults were also found in two DCS trials of panic dis-
order. One of the trials reported that panic patients who
received DCS prior to exposures showed greater symp-
toms reduction than those who received placebo prior to
exposures [67]. A similar trial did not find an overall
group effect, but the severely-ill patients showed acceler-
ated symptom reductions [68]. Finally, two DCS trials
were conducted with post-traumatic stress disorder. The
first trial failed to show an overall group difference [69],
but patients with more severe baseline symptoms bene-
fitted more. In contrast, the second trial found that pa-
tients who received DCS reported greater symptoms at
post-treatment than those who received placebo [70].
Several issues are important to consider when evaluating
this literature.
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than to amplify exposure procedures, because several
clinical trials showed faster improvement in the DCS
group in the short term, but equal improvements com-
pared to placebo augmentation in the long term. Second,
some trials found that DCS was only more effective than
placebo in severely ill patients. This suggests that there
might be important patient variables and other moder-
ator variables that predict treatment outcome and re-
sponse to DCS. Finally, dosing and dosing schedule are
of critical importance. The first clinical trial adminis-
tered single DCS doses of 50 mg or 500 mg, and
reported no differences between these doses [33]. Since
then, doses of 50, 100, and 125 mg have been used in
subsequent studies and all doses appear adequate for en-
hancement of exposure therapy. However, the use of sin-
gle 50 mg doses appears to minimize the risk of side
effects and minimize concerns about tolerance to DCS,
while showing relatively reliable effects when adminis-
tered acutely. At higher doses (e.g., 500–1000 mg), espe-
cially when administered chronically, infrequent side
effects occur (e.g., headache, drowsiness). Moreover,
when administered more frequently or at higher doses,
studies found DCS to have relatively weak results, some-
times even weaker than placebo.
In this context, timing is a particularly important clin-
ical issue. As previously suggested [71], administering
DCS too early may prevent important extinction learn-
ing processes from coinciding with the peak of the drug’s
effect. In support of this idea, a meta-analysis of animal
and human DCS studies showed that timing significantly
predicted effect size, such that studies administering
DCS immediately before or after exposure achieved
greater effects than studies administering DCS multiple
hours before exposure [14]. Of the clinical trials
reviewed here, all but one study [56] administered DCS
orally before the exposure sessions, usually 1 hour but
sometimes 2 or more hours prior. This decision has
been based on the fact that peak blood levels of DCS
occur 4 to 6 hours after ingestion. However, it is possible
that key extinction learning processes that may most
benefit from DCS augmentation occur hours after the
end of exposure sessions.
Moreover, timing is important because administering
DCS prior to exposure introduces the possibility that
DCS can augment reconsolidation of fear memories if
the exposure session is unsuccessful. This observation is
consistent with studies showing that DCS not only aug-
ments extinction learning but also enhances reconsolida-
tion of fear memory in animals [47]. The study by Smits
and colleagues showed that, despite the lack of overall
DCS effects, post-session DCS administration did aug-
ment exposure sessions if the exposure sessions were
successful [56]. Therefore, it could be argued that thedecision to administer DCS should be made post-session,
contingent on the level of fear reduced (i.e., extinction
learning achieved) by the end of the session [56]. An-
other possibility is to include a clinical assay to detect
patients who are likely to benefit from DCS-augmented
treatment [60].
Conclusion
A number of preclinical and clinical studies suggest that
DCS may act as a cognitive enhancer during extinction
learning and CBT. However, other studies report nega-
tive findings. Unanswered questions include the optimal
dose and dose timing of DCS, possible interaction effects
with other drugs, the long-term effects of DCS, and the
specificity of the cognitive process that are targeted by
the drug. Future studies examining the nuances of tim-
ing in DCS administration, as well as its interaction with
the success of exposure sessions, can provide valuable
new insights into the mechanisms of DCS and offer new
means of treating some of the most common mental dis-
orders. Once the mechanisms are clearly understood,
future research will be able to explore other, and perhaps
more effective, agents to augment specific processes dur-
ing CBT and other interventions. Other important areas
for future research include the post-session administra-
tion of DCS and the possible effect of DCS on reconsoli-
dation of fear memory. If DCS, in fact, makes “good”
exposures better and “bad” exposures worse, future in-
vestigators will need to identify individuals who are
likely to benefit from DCS augmentation and those who
are not, in line with a general move toward personalized
medicine.
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